SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-023194
Filing Date
2022-11-08
Accepted
2022-11-08 16:04:02
Documents
14
Period of Report
2022-11-08
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K alxo-20221108.htm   iXBRL 8-K 69041
2 EX-99.1 alxo-ex99_1.htm EX-99.1 212757
3 GRAPHIC img62044099_0.jpg GRAPHIC 148612
  Complete submission text file 0000950170-22-023194.txt   608243

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alxo-20221108.xsd EX-101.SCH 2473
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alxo-20221108_pre.xml EX-101.PRE 10520
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alxo-20221108_lab.xml EX-101.LAB 13613
8 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20221108_htm.xml XML 4539
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

IRS No.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 221368804
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences